A Study of Safety, Functional and Anatomical Effect of Squalamine Lactate Ophthalmic Solution, 0.2% Administered Twice Daily in Subjects With Neovascular Age-related Macular Degeneration

Trial Profile

A Study of Safety, Functional and Anatomical Effect of Squalamine Lactate Ophthalmic Solution, 0.2% Administered Twice Daily in Subjects With Neovascular Age-related Macular Degeneration

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Squalamine (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Ohr Pharmaceutical
  • Most Recent Events

    • 25 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment as per Company decision.
    • 04 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top